< Back to previous page
Researcher
Ignace Vergote
- Disciplines:Gynaecology and obstetrics, Nursing, Endocrinology and metabolic diseases
Affiliations
- Gynaecological Oncology (Division)
Member
From1 Jan 2012 → Today
Projects
1 - 10 of 12
- Exploring the heterogeneity of rare ovarian cancerDefining (epi)genomic transition from precursor lesion to invasive rare ovarian cancerFrom1 Apr 2020 → 1 Apr 2024Funding: Own budget, for example: patrimony, inscription fees, gifts
- Predictive genetic markers for targeted therapy in gynaecological malignancies: bridging the gap between “one-size-fits-all” and more personalised treatment approach.From1 Aug 2019 → 11 Oct 2023Funding: FWO Strategic Basic Research Grant
- Comprehensive genomic and transcriptomic analysis of high grade serous ovarian cancer using single-cell RNA-sequencing.From1 Jan 2019 → 31 Dec 2021Funding: Foundations, funds and other with scientific goal
- Searching for new leads in the diagnosis of ovarian cancerFrom1 Oct 2017 → 30 Sep 2021Funding: Foundations, funds and other with scientific goal
- Comprehensive transcriptomic analysis of high-grade serous tubo-ovarian carcinoma using single-cell RNA-sequencing.From1 Mar 2017 → 5 Jul 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- From Never to Always Events: in search for mango-momentsFrom1 Nov 2016 → 31 Oct 2018Funding: Nonprofit institution or equivalents
- FIRST PET-MR: Flmeish interuniversity research simultaneous time-of-flight PET-MR scanner.From14 Aug 2014 → 13 Feb 2019Funding: Own budget, for example: patrimony, inscription fees, gifts
- Flemish interuniversity simultaneous time-of-flight PET-MR scanner for research.From14 Aug 2014 → 13 Feb 2019Funding: Hercules - Large scale research infrastructure
- A drug strategy targeting stabilised mutant p53 to fight metastatic plantinum-resistant ovarian cancer.From1 Oct 2013 → 31 Mar 2019Funding: General Activities (Annex IV)
- Dendritic cell immunotherapy in serous ovarian cancer.From1 Oct 2013 → 30 Sep 2016Funding: FWO fellowships
Publications
1 - 10 of 773
- Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial(2024)
Authors: Ignace Vergote
- Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer(2024)
Authors: Ignace Vergote, Toon Van Gorp
- Reply to B. Mutlu Sütcüoğlu et al.(2024)
Authors: Ignace Vergote
Pages: 1205 - 1206 - TIM3 Checkpoint Inhibition Fails to Prolong Survival in Ovarian Cancer-Bearing Mice.(2024)
Authors: Yani Berckmans, Jolien Ceusters, Ignace Vergote, An Coosemans
Pages: 1147 - Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.(2024)
Authors: Ignace Vergote
Pages: 25 - 32 - Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.(2024)
Authors: Ignace Vergote
Pages: 186 - 193 - Clinical evaluation of a low-coverage whole-genome test for detecting homologous recombination deficiency in ovarian cancer.(2024)
Authors: Ignace Vergote
Pages: 113978 - Statement of the AGO Kommission Ovar, AGO Study Group, NOGGO, AGO Austria, Swiss AGO, BGOG, CEEGOG, GEICO, and SFOG regarding the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in epithelial ovarian cancer.(2024)
Authors: Toon Van Gorp, Ignace Vergote
Pages: 277 - 284 - ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.(2024)
Authors: Frédéric Amant, Ignace Vergote
Pages: 248 - 266 - Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study(2023)
Authors: Ignace Vergote, Els Van Nieuwenhuysen
Pages: 5536 - +
Patents
1 - 1 of 1
- Methods for diagnosing ovarian cancer (Inventor)